Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,967.38
(
1.18%
)
US TECH 100
25,144.00
(
0.00%
)
Dow Jones
48,535.99
(
0.66%
)
Brent Oil
92.68
(
-2.92%
)
Bitcoin
73,701.98
(
-0.67%
)
News Focus
News Focus
Post# of 257406
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122868
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 241857

Friday, 04/01/2022 10:49:12 AM

Friday, April 01, 2022 10:49:12 AM

Post# of 257406
SBTX addendum—The company says it hopes to submit an IND (i.e. a request to start a phase-1 trial) for SBT8230 in 4Q22. As noted in the post I’m replying to, I think SBTX is flailing and there is little reason to think SBT8230 will be an effective agent in treating HBV.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today